Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing session: reset

Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 6 of 6
Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
The KRASG12C inhibitor, MRTX849, provides insight toward therapeutic susceptibility of KRAS mutant cancers
James G Christensen
Mirati Therapeutics, San Diego, CA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRASG12C inhibitor, in advanced solid tumors
Pasi A Jänne
Dana-Farber Cancer Institute, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
  •  
  • Free
  • Unknown permission
    for presentation
  •  
  •  
Chairperson
Ruth Plummer
Northern Institute for Cancer Research, Newcastle, United Kingdom
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
Next generation strategies to overcome adaptive resistance to MAPK-directed therapies
Poulikos Poulikakos
Icahn School of Medicine at Mount Sinai, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Benjamin Bader
Bayer AG, Berlin, Germany
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
  •  
  • Permission not
    granted for presentation
  •  
  •  
Therapeutic response and resistance to pan-RAF inhibition: From bench to clinic and back
Shiva Malek
Genentech, Inc., South San Francisco, CA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 6 of 6